🇺🇸 FDA
Patent

US 11142765

Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof

granted A61PA61P21/00A61P27/02

Quick answer

US patent 11142765 (Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof) held by Benitec IP Holdings Inc. expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Benitec IP Holdings Inc.
Grant date
Tue Oct 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61P, A61P21/00, A61P27/02